Senturi Pharma Secures European PERTZYE Distribution Deal
Senturi Pharma and Digestive Care, Inc. have signed an exclusive agreement to bring PERTZYE to European markets.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you believe pharmaceutical distribution partnerships generally make life-saving treatments more accessible in your area?
Senturi Pharma has entered into an exclusive distribution partnership with Bethlehem-based Digestive Care, Inc. to provide PERTZYE to European patients. The medication is used for treating exocrine pancreatic insufficiency.
Why it matters
The deal expands access to specialized medical treatments for patients across Europe who require the FDA-approved pancreatic insufficiency therapy.
Digestive Care, Inc., which manufactures the bicarbonate-buffered microsphere treatment, was established in 1990. Senturi Pharma operates its primary European distribution efforts from its headquarters in Stockholm, Sweden.
The players
Senturi Pharma
Senturi Pharma is a healthcare company based in Stockholm, Sweden, that coordinates international distribution for medical products.
Digestive Care, Inc.
Digestive Care, Inc. is a Pennsylvania-based company founded in 1990 that specializes in the development and manufacture of gastrointestinal treatments.
The details
PERTZYE will be supplied throughout Europe via Named Patient Prescription pathways and other authorized distribution mechanisms. The product relies on bicarbonate-buffered enteric-coated microspheres to support patients suffering from exocrine pancreatic insufficiency.
Timeline
October 16, 2026: Senturi Pharma and Digestive Care, Inc. finalized the distribution agreement.
Market Landscape
This partnership mirrors broader trends in the pharmaceutical sector where specialized manufacturers outsource regional distribution to navigate local healthcare regulatory environments. It strengthens the competitive footprint of both companies by leveraging existing clinical approvals to reach international patient populations.
Patients and healthcare providers in Europe gain a new avenue to access PERTZYE through existing Named Patient Prescription pathways. This ensures that the treatment is available to those with exocrine pancreatic insufficiency through authorized medical channels.
The takeaway
This partnership streamlines the path for European patients to receive specialized pancreatic treatments originally developed in the United States. Patients should consult their local healthcare providers to understand how the Named Patient Prescription process applies to their specific care plan.
Further reading
Learn more about the latest developments in the global medical sector by visiting the Healthcare news section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical distribution partnerships generally make life-saving treatments more accessible in your area?
